NCT06169956View on ClinicalTrials.gov

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2030

Conditions
Resectable Non-small Cell Lung Cancer
Interventions
DRUG

Neoadjuvant nivolumab in combination with platinum-based chemotherapy

Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics

Trial Locations (1)

87439

RECRUITING

Klinikverbund Allgaeu, Kempten (Allgäu)

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06169956 - An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany | Biotech Hunter | Biotech Hunter